A retrospective study of autologous stem cell mobilization by G-CSF in combination with chemotherapy in patients with multiple myeloma and lymphoma

被引：22
作者：
Zheng, Gaofeng [1 ,2 ]
He, Jingsong [1 ,2 ]
Cai, Zhen [1 ,2 ]
He, Donghua [1 ,2 ]
Luo, Yi [1 ,2 ]
Shi, Jimin [1 ,2 ]
Wei, Guoqing [1 ,2 ]
Sun, Jie [1 ,2 ]
Zheng, Weiyan [1 ,2 ]
机构：
[1] Zhejiang Univ, Bone Marrow Transplantat Ctr, Affiliated Hosp 1, 79 Qingchun Rd, Hangzhou 310001, Zhejiang, Peoples R China
[2] First Hosp Zhejiang Prov, 79 Qingchun Rd, Hangzhou 310001, Zhejiang, Peoples R China
来源：
ONCOLOGY LETTERS | 2020年 / 19卷 / 01期
基金：
中国国家自然科学基金;
关键词：
hematopoietic stem cells; mobilization; separation; collection; influencing factors; multiple myeloma; lymphoma; COLONY-STIMULATING FACTOR; PREDICTIVE FACTORS; TRANSPLANTATION; EFFICIENCY; PLERIXAFOR; IMPACT; REMOBILIZATION; COLLECTION; THERAPY; FAILURE;
D O I：
10.3892/ol.2019.11177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Factors affecting peripheral blood hematopoietic stem cell (PBSC) mobilization and collection were investigated in patients with multiple myeloma (MM) and lymphoma who were undergoing chemotherapy. Clinical data from 128 patients, including 53 MM and 75 malignant lymphoma (7 Hodgkin's lymphoma and 68 non-Hodgkin's lymphoma) cases were retrospectively analyzed. Autologous PBSCs were mobilized using granulocyte-colony stimulating factor (G-CSF) during chemotherapy, and collected using a continuous flow cell separation instrument. The yields of CD34+ cells per kilogram of patient body weight <2.0x10(6)/kg, >2.0x10(6)/kg or >5.0x10(6)/kg were defined as a failure, a success or ideal mobilization, respectively. In MM and lymphoma patients, the success rates of CD34+ cell acquisition were 73.6 (39/53) and 58.7% (44/75), the ideal rates were 43.4 (23/53) and 30.7% (23/75), and the failure rates were 26.4 (14/53) and 41.3% (31/75), respectively. Univariate and multivariate statistical analysis revealed that negative factors for PBSC mobilization in patients with MM were lenalidomide treatment, multiple chemotherapies, incomplete disease remission and low-level blood hemoglobin; in patients with lymphoma, the negative factors were the histological disease type, incomplete disease remission, being beyond the first-line of previous chemotherapy, multiple chemotherapies, chemotherapy with the HyperCVAD-B mobilization scheme, high-dose MTX/Ara-c (methotrexate/cytarabine) treatment, prolonged administration of G-CSF and low-hematocrit levels. In the present study, different factors influencing PBSC mobilization and collection in MM and lymphoma cases were identified. PBSC mobilization yielded sufficient CD34+ cell counts both in MM and lymphoma patients; however, the failure rates were relatively high.
引用
收藏
页码：1051 / 1059
页数：9
相关论文
共 34 条
[1]   A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor [J].
Abhyankar, S. ;
DeJarnette, S. ;
Aljitawi, O. ;
Ganguly, S. ;
Merkel, D. ;
McGuirk, J. .
BONE MARROW TRANSPLANTATION, 2012, 47 (04) :483-487
[2]  
[Anonymous], 2008, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
[3]   Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience [J].
Arcaini, Luca ;
Laszlo, Daniele ;
Rizzi, Silvia ;
Balzarotti, Monica ;
Antoniazzi, Francesca ;
Zilioli, Vittorio Ruggero ;
Guggiari, Elena ;
Farina, Lucia ;
Todisco, Elisabetta ;
Bonfichi, Maurizio ;
Alamos, Sara Miqueleiz ;
Rossi, Giuseppe ;
Martinelli, Giovanni ;
Morra, Enrica .
LEUKEMIA RESEARCH, 2011, 35 (06) :712-714
[4]   Intermediate doses of cytarabine plus granulocyte-colony-stimulating factor as an effective and safe regimen for hematopoietic stem cell collection in lymphoma patients with prior mobilization failure [J].
Calderon-Cabrera, Cristina ;
Carmona Gonzalez, Magdalena ;
Martin, Jesus ;
Rios Herranz, Eduardo ;
Noguerol, Pilar ;
De la Cruz, Fatima ;
Carrillo, Estrella ;
Falantes, Jose F. ;
Parody, Rocio ;
Espigado, Ildefonso ;
Perez-Simon, Jose A. .
TRANSFUSION, 2015, 55 (04) :875-879
[5]   Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients [J].
Clark, R. E. ;
Bell, J. ;
Clark, J. O. ;
Braithwaite, B. ;
Vithanarachchi, U. ;
McGinnity, N. ;
Callaghan, T. ;
Francis, S. ;
Salim, R. .
BLOOD CANCER JOURNAL, 2014, 4 :e255-e255
[6]   Autologous Stem Cell Mobilization in the Age of Plerixafor [J].
Cooper, Dennis L. ;
Medoff, Erin ;
Patel, Natalie ;
Baker, Julie ;
Pratt, Kathryn ;
Foss, Francine ;
Seropian, Stuart E. ;
Perreault, Sarah ;
Wu, Yanyun .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (07) :411-416
[7]   G-CSF-MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS FOR ALLOGENEIC TRANSPLANTATION - SAFETY, KINETICS OF MOBILIZATION, AND COMPOSITION OF THE GRAFT [J].
DREGER, P ;
HAFERLACH, T ;
ECKSTEIN, V ;
JACOBS, S ;
SUTTORP, M ;
LOFFLER, H ;
MULLERRUCHHOLTZ, W ;
SCHMITZ, N .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (03) :609-613
[8]   Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data [J].
Duarte, R. F. ;
Shaw, B. E. ;
Marin, P. ;
Kottaridis, P. ;
Ortiz, M. ;
Morante, C. ;
Delgado, J. ;
Gayoso, J. ;
Goterriz, R. ;
Martinez-Chamorro, C. ;
Mateos-Mazon, J. J. ;
Ramirez, C. ;
de la Rubia, J. ;
Achtereekte, H. ;
Gandhi, P. J. ;
Douglas, K. W. ;
Russell, N. H. .
BONE MARROW TRANSPLANTATION, 2011, 46 (01) :52-58
[9]   The efficiency of PBPC collections and the relationship to the precollection concentration of CD 34+cells in blood [J].
Gasová, Z ;
Marinov, I ;
Hrubá, A ;
Benesová, K ;
Turek, P .
TRANSFUSION SCIENCE, 1999, 20 (03) :181-188
[10]   Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma [J].
Gertz, M. A. ;
Wolf, R. C. ;
Micallef, I. N. M. ;
Gastineau, D. A. .
BONE MARROW TRANSPLANTATION, 2010, 45 (09) :1396-1403
1234